Raymond N. DuBois
YOU?
Author Swipe
View article: Supplementary Fig. 4 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity
Supplementary Fig. 4 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity Open
Supplementary Fig. 4 shows the densitometric analysis of western blot results presented in Fig. 3.
View article: Supplementary Fig. 1 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity
Supplementary Fig. 1 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity Open
Supplementary Fig. 1 shows PPARδ inhibits CD8+ T cell cytolytic activity.
View article: Supplementary Fig. 2 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity
Supplementary Fig. 2 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity Open
Supplementary Fig. 2 shows PPARδ negatively regulates the expression of perforin, granzyme B, and IFNγ.
View article: Supplementary Fig. 6 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity
Supplementary Fig. 6 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity Open
Supplementary Fig. 6 shows the densitometric analysis of western blot results presented in Fig. 5.
View article: Supplementary Fig. 3 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity
Supplementary Fig. 3 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity Open
Supplementary Fig. 3 shows RelA and PPARδ bind to the same DNA fragments of IFNγ, granzyme B, or perforin gene promoters in human CTLs.
View article: Supplementary Fig. 5 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity
Supplementary Fig. 5 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity Open
Supplementary Fig. 5 shows PPARδ inhibits RelA/p50 DNA binding activity.
View article: Supplementary Fig. 1 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity
Supplementary Fig. 1 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity Open
Supplementary Fig. 1 shows PPARδ inhibits CD8+ T cell cytolytic activity.
View article: Supplementary Fig. 3 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity
Supplementary Fig. 3 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity Open
Supplementary Fig. 3 shows RelA and PPARδ bind to the same DNA fragments of IFNγ, granzyme B, or perforin gene promoters in human CTLs.
View article: Figure 2 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity
Figure 2 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity Open
PPARδ negatively regulates the expression of perforin, granzyme B, and IFNγ. A, Western blot expression of PPARδ in naive, activated, and cytotoxic murine or human CD8+ T cells. B, Western blot expression of indica…
View article: Figure 4 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity
Figure 4 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity Open
PPARδ inhibits RelA/p50 DNA-binding activity. A–C, DNA-binding activity of RelA and p50 in the nucleus of Ppard+/+ and Ppard−/− murine CTLs (A), human CTLs transfected with pl…
View article: Figure 3 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity
Figure 3 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity Open
PPARδ binds RelA and interferes with the RelA/p50 heterodimer formation. A, Interaction of RelA with PPARδ in nuclear extracts of human CTLs was revealed by two-way coimmunoprecipitations. B, RelA, p50, and PPARδ form a κB si…
View article: Supplementary Fig. 4 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity
Supplementary Fig. 4 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity Open
Supplementary Fig. 4 shows the densitometric analysis of western blot results presented in Fig. 3.
View article: Supplementary Fig. 5 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity
Supplementary Fig. 5 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity Open
Supplementary Fig. 5 shows PPARδ inhibits RelA/p50 DNA binding activity.
View article: Supplementary Fig. 6 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity
Supplementary Fig. 6 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity Open
Supplementary Fig. 6 shows the densitometric analysis of western blot results presented in Fig. 5.
View article: Figure 1 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity
Figure 1 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity Open
PPARδ inhibits CD8+ T-cell activation in vivo and cytolytic activity in vitro. A, Proliferation of CFSE-labeled CD8+ T cells from small intestine tumors and adjacent normal tissues in control and …
View article: Supplementary Fig. 2 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity
Supplementary Fig. 2 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity Open
Supplementary Fig. 2 shows PPARδ negatively regulates the expression of perforin, granzyme B, and IFNγ.
View article: Figure 5 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity
Figure 5 from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity Open
RelA, IFNγ, and granzyme B are critical for CTL cytolytic activity. A, Western blot expression of indicated proteins in human CTLs transfected with a plasmid expressing RelA or PPARδ and ELISA expression of IFNγ in the culture media…
View article: Data from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity
Data from Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8<sup>+</sup> T Cells by Inhibiting RelA DNA-Binding Activity Open
The molecular mechanisms regulating CD8+ cytotoxic T lymphocytes (CTL) are not fully understood. Here, we show that the peroxisome proliferator–activated receptor δ (PPARδ) suppresses CTL cytotoxicity by inhibiting RelA DNA bind…
View article: Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8+ T Cells by Inhibiting RelA DNA-Binding Activity
Peroxisome Proliferator–Activated Receptor δ Suppresses the Cytotoxicity of CD8+ T Cells by Inhibiting RelA DNA-Binding Activity Open
The molecular mechanisms regulating CD8+ cytotoxic T lymphocytes (CTL) are not fully understood. Here, we show that the peroxisome proliferator–activated receptor δ (PPARδ) suppresses CTL cytotoxicity by inhibiting RelA DNA binding. Treatm…
View article: FIGURE 3 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
FIGURE 3 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors Open
TPST-1495 is more effective than a single EP4 or EP2 antagonists in overcoming PGE2-mediated immune suppression of recovery of cytokine production from human monocytes and T cells. TNFα ELISA from PGE2 blockade assay performed using human …
View article: TABLE 1A from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
TABLE 1A from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors Open
Prostaglandin pathway inhibitor drugs
View article: FIGURE 5 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
FIGURE 5 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors Open
TPST-1495 exhibits immune-independent antitumor activity. CT26 tumor longitudinal outgrowth of WT and RAG2−/− mice treated with 100 mg/kg TPST-1495 BID for 2 weeks (A) and day 14 volumetric comparisons between mouse group…
View article: FIGURE 2 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
FIGURE 2 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors Open
TPST-1495 is more effective than a single EP4 or EP2 antagonists in overcoming PGE2-mediated immune suppression of recovery of cytokine production from murine monocytes and T cells. A, Schematic of PGE2 blockade assay. Murine whole …
View article: TABLE 1B from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
TABLE 1B from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors Open
Antibodies used for IHC of APCmin/+ tumors
View article: TABLE 1B from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
TABLE 1B from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors Open
Antibodies used for IHC of APCmin/+ tumors
View article: FIGURE 1 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
FIGURE 1 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors Open
Expression profiles of PGE2 receptors EP2 and EP4 across diverse human malignancies. A, Expression of EP2 (PTGER2) and EP4 (PTGER4) across cancer indications indicated in the figure using RNA sequencing data from TCGA …
View article: FIGURE 6 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
FIGURE 6 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors Open
TPST-1495 effectively increases survival and modulates the TME in APCmin/+ mice. A, Tumor counts in the small intestine of APCmin/+ mice. Mice were treated starting at 13 weeks of age for 3 weeks with TPST-1495…
View article: FIGURE 3 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
FIGURE 3 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors Open
TPST-1495 is more effective than a single EP4 or EP2 antagonists in overcoming PGE2-mediated immune suppression of recovery of cytokine production from human monocytes and T cells. TNFα ELISA from PGE2 blockade assay performed using human …
View article: FIGURE 5 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
FIGURE 5 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors Open
TPST-1495 exhibits immune-independent antitumor activity. CT26 tumor longitudinal outgrowth of WT and RAG2−/− mice treated with 100 mg/kg TPST-1495 BID for 2 weeks (A) and day 14 volumetric comparisons between mouse group…
View article: TABLE 1C from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
TABLE 1C from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors Open
Antibodies used for IHC of CT26 tumors